Jessica C L Notohardjo (Jessica Notohardjo)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Locally Advanced

Emergency Department

Squamous Cell Carcinoma

Top Venues

Cancer chemotherapy and pharmacology

Clinical cancer research : an official journal of the American Association for Cancer Research

Science immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Laurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia, J Maxime van Berge Henegouwen, Gijs F de Wit, Louisa R Hoes, Hanneke van der Wijngaart, Vincent van den Noort, Paul Roepman, Wendy W J de Leng, Anne M L Jansen, Myriam Chalabi, Carla M L van Herpen, Lot A Devriese, Frans L G Erdkamp, Mariette Labots, Maja J A de Jonge, Emile D Kerver, Adriaan D Bins, Lindsay V M Leek, Jessica C L Notohardjo, Alfonsus J M van den Eertwegh, Lodewyk F A Wessels, Henk M W Verheul, André B P van Kuilenburg, Joris van de Haar, Emile E Voest
The innate immune landscape of dMMR/MSI cancers predicts outcome of nivolumab treatment: results from the Drug Rediscovery Protocol. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Marise R Heerma van Voss, Jessica C L Notohardjo, Joyce M van Dodewaard-de Jong, Haiko J Bloemendal, Rob Ter Heine
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients. Cancer chemotherapy and pharmacology (2024)
Marise R Heerma van Voss, Jessica C L Notohardjo, Joyce M van Dodewaard-de Jong, Haiko J Bloemendal, Rob Ter Heine
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients. Cancer chemotherapy and pharmacology (2024)
Marise R Heerma van Voss, Jessica C L Notohardjo, Joyce M van Dodewaard-de Jong, Haiko J Bloemendal, Rob Ter Heine
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients. Cancer chemotherapy and pharmacology (2024)
Kim M van Pul, Jessica C L Notohardjo, Marieke F Fransen, Bas D Koster, Anita G M Stam, Dafni Chondronasiou, Sinéad M Lougheed, Joyce Bakker, Vinitha Kandiah, M Petrousjka van den Tol, Karin Jooss, Ronald J C L M Vuylsteke, Alfonsus J M van den Eertwegh, Tanja D de Gruijl
Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T reg reduction and effector T cell activation. Science immunology 7 (73) (2022)